Navigate Fool.com
Will ECYT beat
the market?

Endocyte, Inc. (NASDAQ: ECYT)

Community Rating: 4 Stars: Favorite

6.31 0.07 (1.12%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $6.24
Previous Close $6.24
Daily Range $6.21 - $6.45
52-Week Range $6.01 - $33.70
Market Cap $261.9M
P/E Ratio -13.00
Dividend (Yield) $0.00 (0.0%)
Volume 795,963
Average Daily Volume 1,267,709
Current FY EPS -$0.34

How do you think ECYT
will perform against the market?

Top ECYT Bull/Bear Pitches


zzlangerhans (< 20)
Submitted September 25, 2013

When Endocyte ran over 16 in July I was skeptical of the steep climb and cautioned longs that it might be wise to take some gains off the table. The stock proceeded to run as high as 19, so when it be … More

4 Replies Reply Report this Post

SkepBioInvestor (< 20)
Submitted February 25, 2014

No need to say more: <a href="http://www.thestreet.com/story/12441443/1/the-endocyte-bear-thesis-why-march-will-be-a-bad-month.html">http://www.thestreet.com/story/12441443/1/the-endocyte-bear-thesis- … More

0 Replies Reply Report this Post

News & Commentary

This Week in Biotech: A Double-Dose of Hot Potato

Two pharma giants walk away from collaborations, another investigational drug receives the breakthrough designation, and more M&A activity are this week's biggest biotech stories.

Down 14%: Is Endocyte a Bad News Buy?

Endocyte shares had a rough day -- is now a good time to get into the stock?

Wednesday’s Top Biotech Stories: Insmed, Endocyte, and GW Pharmaceuticals

Insmed, Endocyte, Merck, and GW Pharmaceuticals could all loom large in biotech headlines this Wednesday morning.

Why Endocyte Inc. Shares Plummeted in After Hours

Endocyte shares tumble in after hours after Merck walks away from its collaborative relationship. See what this means for investors going forward.

After Hours Most Active for Jun 17, 2014 : ETE, TD, ADBE, QQQ, ECYT, RY, BAC, TGT, ESRX, MFC, MRVL,

After Hours Most Active for Jun 17, 2014 : ETE, TD, ADBE, QQQ, ECYT, RY, BAC, TGT, ESRX, MFC, MRVL, SIRI

Biotech Bad News Buys

The Biotech Banter crew breaks down recent drops in Seattle Genetics, Pharmacyclics, and Endocyte.

What Biotech Investors Need to Know About Phase 2 Trials

Phase II is an in-between time in clinical development and results can be difficult to place in context. Investors should take into account factors such as rigor of study design, validation of mechanism or concept, and emerging safety signals.

The Biggest Biotech Catastrophes of the Week

See which companies suffered the worst clinical setbacks in the week ending May 2.

3 Stocks Near 52-Week Lows Worth Buying

Do these three fallen angels deserve a second chance? You be the judge!

5 of Last Week's Biggest Losers

These five stocks suffered double-digit percentage declines last week.

See More ECYT News...





Endocyte, Inc. (ECYT) Description

Endocyte Inc is a biopharmaceutical Company developing targeted therapies for the treatment of cancer and inflammatory diseases. It uses its proprietary technology to create novel small molecule drug conjugates or SMDCs and companion imaging diagnose. Website: http://www.endocyte.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks